Mumbai, Feb. 14 -- Zydus Lifesciences announced that the USFDA conducted a surveillance inspection at the group's API Manufacturing site situated at Ambernath in Maharashtra. The inspection was conducted from February 10th to 14th, 2025.

The inspection concluded with NIL observations.

Published by HT Digital Content Services with permission from Capital Market....